9PT Stock Overview A clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Pliant Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Pliant Therapeutics Historical stock prices Current Share Price US$32.00 52 Week High US$33.00 52 Week Low US$3.98 Beta 1.38 1 Month Change 0% 3 Month Change -0.62% 1 Year Change 420.33% 3 Year Change n/a 5 Year Change n/a Change since IPO 48.15%
Recent News & Updates
Pliant Therapeutics Appoints Gary Palmer as Senior Vice President of Medical Affairs Oct 02
Pliant Therapeutics, Inc. Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Jul 15
Pliant Therapeutics, Inc.(NasdaqGS:PLRX) dropped from Russell 2500 Growth Index Jul 03
Pliant Therapeutics, Inc. Appoints Steve Krognes to Its Board of Directors Jun 15
Pliant Therapeutics, Inc. Announces Positive Topline Data from A Phase 2A Collagen Pet Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis May 15
Pliant Therapeutics, Inc., Annual General Meeting, Jun 13, 2024 Apr 23 See more updates
Pliant Therapeutics Appoints Gary Palmer as Senior Vice President of Medical Affairs Oct 02
Pliant Therapeutics, Inc. Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Jul 15
Pliant Therapeutics, Inc.(NasdaqGS:PLRX) dropped from Russell 2500 Growth Index Jul 03
Pliant Therapeutics, Inc. Appoints Steve Krognes to Its Board of Directors Jun 15
Pliant Therapeutics, Inc. Announces Positive Topline Data from A Phase 2A Collagen Pet Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis May 15
Pliant Therapeutics, Inc., Annual General Meeting, Jun 13, 2024 Apr 23
Pliant Therapeutics, Inc. Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis Mar 13
Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis Feb 05
Pliant Therapeutics, Inc. Appoints S. Mishima Gerhart as Chief Regulatory Officer Oct 17
Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis Sep 27
Pliant Therapeutics, Inc. Appoints Minnie Kuo as Chief Development Officer Sep 16
Pliant Therapeutics, Inc. Presents Data from Its Bexotegrast Program At the European Association for the Study of the Liver International Liver Congress Jun 24
Pliant Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors Feb 03 Pliant Therapeutics, Inc. Appoints Lily Cheung as Chief Human Resources Officer
Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Jan 23
Insufficient new directors Jan 01
Pliant Therapeutics, Inc. Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis Dec 16
Neil Exter to Retire as Member of the Board of Directors of Pliant Therapeutics Nov 19
Third quarter 2022 earnings released: US$0.65 loss per share (vs US$0.75 loss in 3Q 2021) Nov 10
Pliant Therapeutics Appoints Katharine Knobi to Board of Directors Sep 16
Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis Sep 02
Second quarter 2022 earnings released: US$0.82 loss per share (vs US$0.64 loss in 2Q 2021) Aug 10
Pliant Therapeutics Receives FDA Fast Track Designation for Pln-74809 for the Treatment of Primary Sclerosing Cholangitis Jul 22
Pliant Therapeutics, Inc. Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis Jul 11 Pliant Therapeutics, Inc.(NasdaqGS:PLRX) dropped from Russell 2000 Growth Index
Pliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies Jun 23
Pliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration Jun 17
Pliant Therapeutics, Inc. Presents Five Scientific Posters as Part of the 2022 American Thoracic Society International Conference May 19
First quarter 2022 earnings released: US$0.78 loss per share (vs US$0.64 loss in 1Q 2021) May 10
Pliant Therapeutics, Inc., Annual General Meeting, Jun 16, 2022 May 02
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 02
Pliant Therapeutics Announces Positive Data from Expanded Phase 1b BAL Trial of PLN-74809 Demonstrated Suppression of TGF-ß Signaling in Healthy Volunteers Mar 01
Pliant Therapeutics, Inc. Announces Positive DSMB Safety Review and Commencement of Enrollment of Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis Feb 25
Pliant Therapeutics Highlights Recent Developments for Lead Program Pln-74809 and Expected 2022 Milestones Jan 13
Third quarter 2021 earnings released: US$0.75 loss per share (vs US$0.47 loss in 3Q 2020) Nov 10
Pliant Therapeutics, Inc. Reports Positive Interim Results from Phase 2a PET Imaging Clinical Trial in Patients with Idiopathic Pulmonary Fibrosis Sep 08
Second quarter 2021 earnings released: US$0.64 loss per share (vs US$1.39 loss in 2Q 2020) Aug 10
First quarter 2021 earnings released: US$0.64 loss per share May 12
Pliant Therapeutics, Inc. Announces Successful Completion of PLN-1474 Phase 1 Study and Development Transition to Global Pharmaceutical Partner Mar 17
Investor sentiment improved over the past week Mar 13
Investor sentiment improved over the past week Feb 25
New 90-day high: €28.60 Feb 24
Investor sentiment improved over the past week Feb 04
New 90-day high: €26.40 Feb 04
Pliant Therapeutics, Inc. Announces Appointment of David Pyott to Board of Directors Jan 13
Investor sentiment improved over the past week Jan 11
New 90-day high: €24.21 Nov 19
Pliant Therapeutics Appoints Mike Ouimette as General Counsel and Corporate Secretary Oct 06
New 90-day low: €19.00 Sep 29 Pliant Therapeutics, Inc. announced that it expects to receive $45 million in funding Shareholder Returns 9PT DE Pharmaceuticals DE Market 7D 0% 2.2% 0.7% 1Y 420.3% -16.8% 8.4%
See full shareholder returns
Return vs Market: 9PT exceeded the German Market which returned 6.3% over the past year.
Price Volatility Is 9PT's price volatile compared to industry and market? 9PT volatility 9PT Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 12.0% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 9PT's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 9PT's volatility change over the past year.
About the Company Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company’s lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase IIa trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. It also develops PLN-1474, a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies.
Show more Pliant Therapeutics, Inc. Fundamentals Summary How do Pliant Therapeutics's earnings and revenue compare to its market cap? 9PT fundamental statistics Market cap €1.52b Earnings (TTM ) -€111.91m Revenue (TTM ) €8.79m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 9PT income statement (TTM ) Revenue US$9.69m Cost of Revenue US$0 Gross Profit US$9.69m Other Expenses US$133.01m Earnings -US$123.32m
Last Reported Earnings
Dec 31, 2022
Earnings per share (EPS) -2.08 Gross Margin 100.00% Net Profit Margin -1,273.32% Debt/Equity Ratio 3.2%
How did 9PT perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2023/04/30 14:14 End of Day Share Price 2023/01/31 00:00 Earnings 2022/12/31 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Pliant Therapeutics, Inc. is covered by 17 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Edward Nash Canaccord Genuity Pete Stavropoulos Cantor Fitzgerald & Co. David Lebowitz Citigroup Inc
Show 14 more analysts 
